CAR T-Cell Therapies: Overcoming the Challenges and New Strategies

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for patients with advanced lymphoid malignancies. Response rates up to 90% have been reported for patients with refractory B-lineage acute lymphoblastic leukemia (ALL).1-4 Much has been learned since the excitement of the first reported case using CAR T cell therapy for the successful treatment of a patient with multiply relapsed chronic lymphocytic leukemia (CLL).5 Pre-clinical and clinical trials are underway in other malignancies, including multiple myeloma, acute myeloid leukemia, and solid tumors.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research